Work

939TiP Phase II multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy of HB-200 in patients with detectable TTMV-HPV DNA after definitive treatment for HPV16 + HNSCC

Year: 2024

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2024.08.1000

Authors: A.L. Ho, N. Riaz, D. Pfister, R. Wong, N. Lee, E.J. Sherman, S. Haque, I. Ostrovnaya, W. Wong

Institution: Memorial Sloan Kettering Cancer Center

Language: English

Topic: Head and Neck Cancer Studies

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Pfizer, AstraZeneca, Sanofi, Regeneron Pharmaceuticals, Les Laboratories Pierre Fabre, Moderna, Castle Biosciences, Seagen, Natera, NeraCare, InflaRx

OpenAlex ID: W4402561204

FWCI: 0.384

Cites:

Cited by: 1

Related to: 10